Shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) traded down 6.3% during trading on Monday . The company traded as low as $16.93 and last traded at $17.05. 1,467,975 shares were traded during trading, an increase of 18% from the average session volume of 1,241,289 shares. The stock had previously closed at $18.20.

A number of analysts have recently commented on the stock. Morgan Stanley assumed coverage on shares of Alder Biopharmaceuticals in a research note on Monday, September 10th. They set an “underweight” rating and a $19.00 target price for the company. BidaskClub cut shares of Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 28th. ValuEngine cut shares of Alder Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 24th. Cantor Fitzgerald assumed coverage on shares of Alder Biopharmaceuticals in a research note on Wednesday, August 22nd. They set a “neutral” rating and a $21.00 target price for the company. Finally, Zacks Investment Research raised shares of Alder Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research note on Monday, August 20th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $23.33.

The company has a market cap of $1.24 billion, a PE ratio of -3.25 and a beta of 2.59. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.73.

Alder Biopharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.01. analysts predict that Alder Biopharmaceuticals Inc will post -4.73 earnings per share for the current year.

In related news, Director Jeffrey T. L. Smith sold 5,040 shares of the company’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $19.54, for a total transaction of $98,481.60. Following the completion of the sale, the director now owns 5,871 shares of the company’s stock, valued at approximately $114,719.34. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey T. L. Smith sold 12,161 shares of the company’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $15.49, for a total transaction of $188,373.89. Following the sale, the director now directly owns 7,952 shares of the company’s stock, valued at approximately $123,176.48. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 97,238 shares of company stock valued at $1,703,022. 17.40% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in ALDR. Flinton Capital Management LLC acquired a new position in Alder Biopharmaceuticals in the 1st quarter valued at about $100,000. SG Americas Securities LLC acquired a new position in Alder Biopharmaceuticals in the 2nd quarter valued at about $107,000. Neuburgh Advisers LLC acquired a new position in Alder Biopharmaceuticals in the 1st quarter valued at about $121,000. Tower Research Capital LLC TRC acquired a new position in Alder Biopharmaceuticals in the 2nd quarter valued at about $128,000. Finally, Xact Kapitalforvaltning AB acquired a new position in Alder Biopharmaceuticals in the 1st quarter valued at about $142,000.

Alder Biopharmaceuticals Company Profile (NASDAQ:ALDR)

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.

Recommended Story: Diversification Important in Investing

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.